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METHODS 
Participants 
EPIC investigates the role of biological, dietary and lifestyle factors in the aetiology 
of cancer and other chronic diseases. More than 521,000 apparently healthy men and 
women, aged 25 to 70 years, were recruited between 1992 and 2000 in 23 centres 
from 10 European countries (Denmark, France, Germany, Greece, Italy, the 
Netherlands, Norway, Spain, Sweden, and United Kingdom (UK)). The participants 
were selected from the general population, except for France (women-members of 
health insurance plans), Utrecht and Florence (women - breast cancer screening), 
Naples and Norway (women only), the Oxford cohort (which includes a large 
proportion of vegetarian volunteers) and subsamples of the Italian and Spanish 
cohorts (mainly members of blood donor associations).  Details of EPIC are given 
elsewhere.10    
 
The study was approved by the Ethical Review Board of the International Agency for 
Research on Cancer, and by the local Ethics Committees in the participating centres. 
Participants gave informed consent before enrolment. Procedures were in line with the 
Helsinki declaration.  
 
Assessment of diet 
Dietary intakes over the previous year were assessed at enrolment through validated 
centre-specific questionnaires which enquired also about cups of coffee and tea 
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consumption per day, week or month.11 In some centres, additional information on 
caffeinated and decaffeinated coffee consumption was obtained (Germany, Greece, 
Italy (except Ragusa and Naples), Netherlands, and UK). Information on tea 
consumption was not available in Norway.  Data on type of tea were not available. 
Based on the information collected by the questionnaires, beverage intakes were 
calculated in each center in ml/day in order to take into account differences in cup 
sizes by region.  Total energy intake was calculated through the EPIC Nutrient-Data-
Base.12   
   
Assessment of lifestyle, somatometry and medical history  
At enrolment, standardized questionnaires were used to record sociodemographic, 
lifestyle and medical history data.  Measurements of weight, height and waist/hip 
circumferences were undertaken for most participants- in France, Norway and 
Oxford, self-reported weight and height were recorded for the majority of the 
participants 
 
Follow-up of study population and case ascertainment 
Incident HCC cases and vital status were ascertained in most centres through record 
linkage with cancer and death registries.  In France, Germany and Greece a 
combination of methods was used including health insurance records, pathology 
registries and active follow-up through mailed questionnaires/telephone interviews.  
Reported incident cancers were subsequently verified through pathology reports, 
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medical records and discharge diagnoses.  Cancer incidence was coded according to 
the International Classification of Diseases-Oncology-2.  HCC was defined as C22.0. 
 
Censoring dates for cancer incidence for centres using registry data ranged from 
December 2004 (Asturias (Spain)) to December 2008 (Turin (Italy), Sweden and 
Norway).  For centres using active follow-up, last contact ranged from July 2005 
(France) to June 2010 (Heidelberg (Germany)). 
 
From the 521,330 EPIC participants, we excluded 23,818 with prevalent cancer, 4,383 
with insufficient follow-up, 78 cases with metastatic cancer or ineligible information 
on histology, 6,192 with no dietary and 60 with no lifestyle questionnaires.  
Eventually, 486,799 participants including 201 incident HCC cases were analysed.  
 
Nested case-control study  
Within EPIC, a nested case-control study, using data as of 2006 on 125 HCC cases 
and 250 matched controls was conducted.13 For these, serum levels of hepatitis B 
surface antigen (HBsAg) and antibodies to hepatitis C virus (anti-HCV) were 
determined at the Centre de Biologie République laboratory in Lyon, France.  Design 
and methods of this study have been described elsewhere.13 Controls were selected 
from those alive and free of cancer at the time of diagnosis of the case.  Matching 
criteria included study centre, sex, age at the time of blood collection, date and time of 
day of blood collection.  Women were additionally matched by menopausal status and 
by use of exogenous hormones.   
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Statistical analysis   
The associations of coffee, caffeinated/decaffeinated coffee, and tea intake with HCC 
risk were investigated through Cox proportional hazard models.  Age at exit was the 
underlying time variable defined as the age of: HCC diagnosis (case); diagnosis of 
any other incident cancer (censored); death for participants who died without cancer 
(censored); last follow-up for those alive and with no cancer (censored). Age at 
recruitment was the entry time.  All models were stratified by recruitment age (1-year 
intervals) and study centre. 
 
Coffee intake was considered in sex-specific quintiles (Q1-Q5).  For tea, due to the 
large number of non-consumers (153,097/450,921, 34%), five categories of intake 
(C1-C5) were created: non-consumers (C1) and the sex-specific quartiles (C2-C5) 
among consumers.  Both variables were considered categorically and per one-level 
increments.  Norway was excluded from tea analyses, as no relevant data were 
available.  Due to potential between-countries variations in coffee/tea volume and 
concentration, we also based estimation of quintiles of coffee and categories of tea on 
sex-and-country specific intakes in order to check the robustness of our findings.  
Linear trends were evaluated using the medians of quintiles/categories as continuous 
variables in the Cox models.  In additional models, coffee and tea were mutually 
adjusted for. 
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In analyses by type of coffee, only data from 163,672 participants (Germany, 
Netherlands and United Kingdom), for whom the sum of caffeinated and 
decaffeinated coffee equals the total amount of coffee intake, were included.  Due to 
the large number of non-consumers of decaffeinated coffee (35%) we considered 3 
categories for this beverage: (i) C1: non-consumers, (ii) C2: consumers below the 
median (among consumers), and (iii) C3: consumers at/above the median (among 
consumers). To preserve comparability here, caffeinated coffee and tea were also 
analysed in 3 categories defined as for decaffeinated coffee. 
 
In all analyses, potential confounders were: sex, self-reported diabetes (categorically: 
no, yes, unknown), education (categorically: no formal/primary school, 
technical/secondary school, university /longer, unknown), physical activity 
(categorically: inactive/moderately inactive, moderately active/active, unknown), 
smoking (categorically: never, former smoker, current smoker, unknown), ethanol 
intake (categorically: low: men< 10g/day, women <5 g/day; moderate: men 10-<40 
g/day, women 5-<20 g/day; high: men >40 g/day, women >20 g/day), body mass 
index (categorically: <25 kg/m2, >25 to <30 kg/m2 , >30 kg/m2) and energy intake 
(ordered, in sex-specific quintiles).   In order to minimize residual confounding by 
smoking/ethanol intake, we further used more detailed variables (but with more 
missing values), accounting for intensity and/or duration of smoking and lifetime 
alcohol drinking.  Deviations from log linearity of the associations between coffee/tea 
intakes and HCC risk were assessed by: a) comparing models including coffee/tea 
intakes as ordered, with models including both dietary exposures as categorical, using 
the Likelihood Ratio test (LRtest), b) by applying restricted cubic splines Cox 
regression models for coffee/tea intakes and testing (using the Wald test and the 
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LRtest) whether these models were of better fit as compared to models which 
assumed simpler, log linear associations between coffee/tea and HCC risk, and c) by 
inspecting the Akaike’s Information Criterion (AIC) in models assuming restricted 
cubic splines for the indicated associations as compared to models of linear trends 
which are shown in Table 3.     
 
We performed several sensitivity analyses (see Results). Furthermore, we investigated 
whether the estimated associations differed across strata defined by sex 
(men/women), diabetes (yes/no), smoking (never/former/current), ethanol intake 
(low/moderate/high as indicated above) and body mass index (<25 kg/m2/ >25 to <30 
kg/m2 / >30 kg/m2), by introducing interaction terms between quintiles/categories of 
coffee/tea intake (ordered) and each of the indicated variables (categorically).  In 
order to evaluate whether the associations between coffee/tea intake and HCC risk 
varied by positivity status regarding hepatitis B virus (HBV) and/or hepatitis C virus 
(HCV), we used data from the nested case-control study13 and introduced interaction 
terms in conditional logistic regression models between HBV/HCV status (yes/no) 
and coffee/tea intakes; in this analysis, coffee/tea intakes were considered in tertiles 
(T1-T3, using control-defined cut-off values) due to the small number of controls.   
P<0.05 was considered statistically significant. All analyses were performed using 
STATA (Stata Corporation: Stata statistical software, release 11. College Station. TX: 
Stata Corporation; 2009).  
 RESULTS 
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After a median follow-up of 11 years, 1,622,408 and 3,744,060 person-years were 
accrued from the 145,039 (30%) men and 341,760 (70%) women of the study 
population, respectively, and 133 men and 68 women were diagnosed with HCC.   
 
Table 1 presents the distribution of participants according to sex-specific quintiles of 
coffee intake, country and baseline characteristics. Overall median coffee 
consumption was 354 ml/d among men and 290 ml/d among women; 7% of the 
participants did not consume coffee.  Coffee intake varied across countries, with the 
Danes consuming the highest quantities.  Participants with higher coffee intakes were 
slightly older, more educated, reported less frequently diagnosis with diabetes, were 
more frequently smokers, consumed higher amounts of ethanol, had lower body mass 
index, were more active and had higher energy intake.   
 
In Table 2, corresponding distributions as in Table 1 are presented by categories of tea 
intake.  Among tea consumers (66% of the total cohort), median intakes were 107 
ml/d for men and 190 ml/d for women. Distribution of participants across categories 
of tea intake varied across countries, with the highest intakes consumed in the UK. 
Consumers of high tea intakes were more educated, more active, former smokers, 
moderate ethanol drinkers, reported less frequently diabetes, and had lower body mass 
index.  
 
Table 3 shows hazard ratios (HRs) for HCC incidence by quintiles/categories of 
coffee/tea intakes, separately (models 1 and 2) and after mutual adjustment (model 3). 
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Increased coffee intake was associated with a substantial, monotonic and statistically 
significant reduction in HCC risk, in all models.  This inverse association was more 
pronounced when coffee and tea were considered simultaneously (HRQ5vsQ1, 0.28; 
95% confidence interval (CI), 0.16 to 0.50). Tea intake was also inversely associated 
with HCC incidence, with a linear trend apparent in all models (particularly model 3).  
There was no statistical evidence indicating that models assuming a log linear 
association between coffee/tea intakes and HCC risk were of inferior fit as compared 
to models with no assumption for the type of association of coffee/tea with HCC risk 
(i.e., using  coffee/tea intakes in quintiles/categories, categorically): LRtestcoffee 
=0.707, LRtesttea =0.683.  Similarly, there was no evidence that restricted cubic 
splines regression models were of better fit as compared to simpler models assuming 
log linear associations between coffee/tea and HCC risk (p-value from Wald test: 
coffee: 0.13; tea: 0.78).  The AIC for model 3 of Table 3 of linear trends 
(AIC=2372.795)  indicated a slightly better model fit as compared to the restricted 
cubic splines models for coffee (AIC=2379.004) and tea (AIC= 2409.564).  
 More detailed control for smoking (i.e., smoking intensity/duration) and alcohol 
intake (e.g. lifetime alcohol consumption), as well as, the inclusion of  body mass 
index and energy intake as continuous rather than as categorical variables, generated 
very similar results. 
 
Sensitivity analyses 
Sensitivity analyses focussed on model 3 (Table 3).  When subjects without missing 
values were studied (187 HCC cases/413,666 participants), HRs and 95% CIs were 
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essentially identical to those reported in Table 3. When 9,596 subjects (10 HCC 
cases) in the top/bottom 1% of the energy intake distribution were excluded, results 
were also similar to those previously reported (coffee: HR Q5vsQ1, 0.26; 95% CI, 0.14 
to 0.48 (P-trend <0.001); tea: HR C5vsC1, 0.36; 95% CI, 0.18 to 0.73 (P-trend=0.002)). 
When analyses were restricted to the 167 histologically confirmed HCC cases with tea 
consumption information, the inverse associations of coffee/tea with HCC risk 
followed the same linear trends (coffee: P-trend <0.001; tea P-trend=0.009).  
Excluding the first 2 years of follow-up (171 HCC cases/442,961 participants 
analysed) did not alter the strength/pattern of the estimated associations (coffee: P-
trend <0.001; tea: P-trend=0.002).  Finally, using sex-and-country specific 
quintiles/categories for coffee and tea, resulted in somewhat less striking, albeit still 
statistically significant associations for coffee ( HRQ2vsQ1, 0.57; 95% CI, 0.39 to 0.85; 
HRQ3vsQ1, 0.57; 95% CI, 0.36 to 0.89; HRQ4vsQ1, 0.56; 95% CI, 0.36 to 0.87; HRQ5vsQ1, 
0.45; 95% CI, 0.28 to 0.74; P-trend=0.002).  For tea, the apparent linear trend was no 
longer statistically significant, possibly on account of scarcity of data (P-trend=0.08). 
 
Examination of effect-modifications 
Interactions were evaluated among participants without missing data and were, 
generally, far from statistically significant. The associations of both beverages were 
considerably weaker among diabetics, but the interaction terms were statistically non-
significant (coffee, P-interaction=0.14; tea, P-interaction =0.20).  There was a 
suggestion for tea-by-sex interaction (P-interaction=0.06), possibly on account of the 
small number of female HCC cases; HRs (95% CIs) per category increase in tea 
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consumption were 0.80 (0.68 to 0.94) among men, but 1.08 (0.84 to 1.38) among 
women.   
 
In the nested case-control analysis, odds ratios (OR) for HCC risk, adjusted for 
HBV/HCV status, smoking, ethanol intake, education, and mutually for coffee and tea 
intakes were: coffee:  ORT3vsT1, 0.54 (95% CI, 0.19 to 1.58), P-trend=0.25; tea: 
ORT3vsT1, 0.36 (95% CI, 0.13 to 0.99), P-trend 0.04.  No evidence for effect 
modification of the impact of coffee/tea intakes on HCC risk according to HBV/HCV 
status was observed (coffee: P-interaction=0.78; tea: P-interaction=0.50). 
 
Caffeinated and decaffeinated coffee  
In analyses of 163,672 participants (64 HCC cases) from Germany, Netherlands and 
UK, the inverse association of coffee with HCC risk was seen across the three 
categories of caffeinated (P-trend=0.009), but not of decaffeinated coffee (P-
trend=0.45). Compared to caffeinated coffee, the inverse association of decaffeinated 
coffee with HCC risk was considerably weaker and statistically non-significant 
(HRC2vs.C1: 0.94, 95% CI, 0.39 to 2.28; HR C3vs.C1:0.74, 95% CI, 0.36 to 1.51).  
 
DISCUSSION 
In a multi-centre European cohort, we found evidence that intakes of coffee and, to a 
lesser extent, tea are associated with lower HCC incidence.  Both associations 
followed statistically significant linear trends, which were also generally apparent in 
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subgroup analyses.  Compared to those with minimal or no consumption of coffee, 
and adjusted also for tea intake, those in the highest quintile of coffee intake had a 
statistically significantly lower HCC risk by about 70%. For tea, the corresponding 
contrast was milder than that for coffee, with the risk in the highest quintile being 
about 60% lower in comparison to the lowest quintile (composed exclusively by non-
consumers).  This is the first multi-centre cohort study in a western population which 
has investigated simultaneously and with mutual adjustment the association of coffee 
and tea intakes with HCC risk.  
 
Our results are in line with those reported in previous case-control14-16 and cohort17-22 
Asian studies, as well as in three case-control studies23-25 and in two, moderately-
sized, cohort studies conducted in Europe5,6 with respect to: a) the inverse association 
of coffee consumption with HCC risk, b) the linear trend in risk reduction with 
increasing coffee intake, and c) the consistency of these findings across various 
subgroups.   In a recent meta-analysis,8 including all indicated studies, as well as three 
studies reporting statistically non-significant inverse19,26 or null27 associations, the 
summary relative risk for HCC for any vs. no coffee consumption was 0.60 (95% CI, 
0.50 - 0.71), with a dose-response trend.  With the exception of one Italian case-
control study, 25 studies on tea consumption and HCC risk have been conducted 
exclusively in Asia (where green tea consumption is more frequent than in Europe); 
the results are collectively inconclusive.  Two studies reported statistically significant 
inverse associations,28,29 four inverse but statistically non-significant associations,30-33  
two null associations,19,34 whereas three reported positive, albeit statistically non-
significant associations.17, 25, 35 A meta-analysis of these studies9 pointed to a 
suggestive inverse association of tea with primary liver cancer.  Our study, the first 
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cohort study outside Asia, indicates an inverse, dose-dependent association of tea with 
HCC risk, which is not incompatible with the results of the indicated meta-analysis, 
although our findings point to a stronger inverse association.  
 
Several mechanisms could underlie the inverse association between coffee intake and 
HCC. Coffee has been inversely related to chronic liver disease, 36,37 cirrhosis,37,38 or 
diabetes mellitus.39  In previous studies, however, the inverse association between 
coffee and HCC risk was evident in subjects irrespectively of chronic liver disease, or 
HBV/HCV status.8  When we excluded the first 2 years of follow-up, which would 
exclude a fraction of cases with underlying liver disease, results were largely 
unchanged. Moreover, adjusting for chronic HBV/HCV infection in our nested case-
control study, did not materially affect the results, nor was there a statistically 
significant interaction between virus carrier state and coffee (and tea) intake with 
respect to HCC risk – a finding with considerable clinical importance,40 given the 
high HCC risk of HBV/HCV carriers. Of note, our results were adjusted for diabetes 
and there was no evidence for diabetes-by-coffee (or tea) interaction.  
 
Coffee contains several hundred chemical compounds including caffeine, diterpenes, 
chlorogenic acids and flavonoids, with reported anti-hepatocarginogenic effects.41 
Regarding caffeine intake, in a subset of our data, intake of caffeinated coffee, tea and 
decaffeinated coffee appear to be inversely related to HCC risk but the association is 
strong and statistically significant for caffeinated coffee, weaker and statistically non-
significant for tea and still weaker for decaffeinated coffee.  Taking into account, the 
correspondence with the caffeine content of the three beverages and given that 
caffeine content (not content of other antioxidant compounds)42 is the defining 
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difference between caffeinated and decaffeinated coffee, a key role of caffeine cannot 
be excluded.  We did not have available information on the amount of caffeine intake 
(from all food/beverage sources) in order to better explore the potential role of 
caffeine on the inverse association of coffee with HCC risk.  The possible differential 
association of caffeinated and decaffeinated coffee with HCC risk needs to be further 
explored, preferably in other large cohort studies.  
 
Regarding tea, experimental studies have suggested a hepatoprotective effect, mainly 
invoking antioxidative properties of green tea polyphenols.43 There was no adequate 
information on type of tea in our cohort, but Europeans are likely to consume mostly 
black rather than green tea. Given the inconclusive collective evidence in the 
literature, further studies are needed to affirm any protective role of tea on HCC risk 
before exploring the underlying mechanisms. 
 
Strengths of our study are its cohort design, its multi-centre coverage allowing to 
examine a variable range of tea and coffee intakes across European countries, the use 
of validated questionnaires, the relatively long follow-up, the common identification 
criteria of incident HCC and the available information about potential confounders.  A 
limitation of our study is the unavoidable modest number of HCC outcomes, given the 
low incidence of the disease in most European countries. Another limitation stems 
from the lack of data about brewing methods across countries, as well as from 
complications arising from the different volume/concentration of coffee consumption 
across countries.  Errors in reporting beverage consumption cannot be ruled out, but 
this is more likely to result in random misclassification of intakes, thus generating 
underestimation of true associations.  Bias in the estimated associations could have 
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been introduced if cases had modified their coffee/tea consumption during the 
prediagnostic period of their disease, but excluding cases diagnosed in the first 2-
years of follow-up generated essentially identical results. 
 
In conclusion, in a large prospective study across European countries, we found 
evidence that increased coffee and tea intakes are associated, in a dose-dependent 
pattern, with lower HCC risk.  The estimated risk reduction was stronger for coffee 
than for tea, whereas there was no convincing evidence for an association of 
decaffeinated coffee with HCC.  Given the apparent lack of heterogeneity of the HCC 
associations with coffee and tea by HBV/HCV positivity status or other risk factors, 
the results may even have important implications for high HCC risk subjects. 
Mechanistic studies could clarify whether the noted associations could be attributed to 
caffeine, or, to other constituents of these beverages.   
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Table 1. Distribution of study participants by quintiles
a
 of coffee intake, as well as, by country of origin and baseline characteristics.  The 
European Prospective Investigation into Cancer and nutrition study. 
Quintiles of coffee intake (ml/day) 
Q1 Q2 Q3 Q4 Q5 
Median (range): males 
17.3 
 (0 to 83.3) 
140.5  
(83.3 to 200.4) 
375  
(200.5 to 476.9) 
556.4  
(477.2 to  830.4) 
1000  
(831.3 to 4500) 
Median (range): females 
3.8  
(0 to 60) 
125.9  
(60 to 191.9) 
290.4  
(191.9 to 375) 
500  
(375 to 580.2) 
856.9  
(580.3 to 6250) 
Countryb (%) 
France 22.1 21.9 27.0 16.9 12.0 
Italy 35.6 56.7 7.4 0.3 0.04 
Spain 44.7 34.0 17.8 2.8 0.7 
UK 26.7 20.5 10.9 21.7 20.1 
Netherlands 8.2 5.0 21.8 29.0 36.0 
Greece 22.3 43.8 26.1 6.3 1.5 
Germany 11.9 11.2 32.4 27.9 16.7 
Sweden 7.7 10.5 27.7 32.4 21.7 
Denmark 7.4 6.6 3.1 27.0 55.9 
Norway 14.4 7.2 30.8 25.9 21.7 
Age (years): Mean (SD) 50 (11) 52 (10) 51 (9) 51 (10) 52 (9) 
Sexb (%) 
males 20.4 19.6 21.5 18.5 20.0 
females 20.1 21.2 18.7 20.4 19.6 
Self-reported diabetes mellitusb 
(%) 
No 20.2 21.0 19.6 19.7 19.5 
50
51
52
53
54
55
56
57
58
59
60
34
 
Yes 24.7 24.9 19.3 15.6 15.5 
Unknown 16.2 12.0 18.3 25.5 28.0 
Educational levelb (%) 
None / Primary 23.2 26.9 17.9 14.6 17.4 
Technical/professional/secondary 17.6 17.3 20.4 22.5 22.3 
University degree/longer 20.1 18.9 21.3 21.4 18.4 
Not specified 26.7 22.5 12.4 21.2 17.3 
Smokingb (%) 
Never 24.8 23.0 19.6 19.0 13.6 
Former 18.0 19.0 20.5 21.6 21.0 
Current 12.6 18.0 17.9 19.5 32.0 
Unknown 20.7 19.9 25.8 19.2 14.3 
Ethanol Intake (g/day) b (%) 
low c 23.5 21.2 19.9 18.6 16.8 
moderate c 16.3 19.8 19.3 21.8 22.8 
high c 17.1 21.6 18.8 19.4 23.2 
Body Mass Indexb (kg/m2) (%) 
     <=25 20.1 19.4 20.0 21.0 19.5 
>25 - <30 19.2 21.3 19.5 19.3 20.6 
>=30 22.8 24.5 18.0 16.3 18.4 
Physical Activity Indexb (%) 
moderately inactive d 22.5 24.6 18.8 17.6 16.5 
moderately active d 18.4 18.6 18.5 21.3 23.2 
unknown 14.2 7.5 28.7 26.3 23.3 
Energy Intake (kcal/day) :  
mean (SD) 2051.4 (686.0) 2109.6 (677.0) 2062.7 (661.1) 2069.8 (662.9) 2130.2 (702.3) 
50
51
52
53
54
55
56
57
58
59
60
35 
 
Total (Number) 98,148 100,953 95,231 96,413 96,054 
a Sex-specific quintiles in the overall cohort 
b Numbers in cells do not always add up to 100% horizontally due to rounding 
c Ethanol Intake: Low: Males:<10 g/day / Females:<5 g/day; Moderate: Males:10g/day to <40g/day / Females:5g/day to 20g/day; High: 
Males:>40 g/day; Females:>20 g/day.   
d Based on occupational physical activity and physical activity during cycling and sports 
 
50
51
52
53
54
55
56
57
58
59
60
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Table 2. Distribution of study participants by categories
a
 of tea intake, as well as, by country of origin and baseline characteristics.  The 
European Prospective Investigation into Cancer and nutrition study. 
Categories of tea intake (ml/day) 
C1 C2 C3 C4 C5 
Median (range): males 0 
3.3 
(0.3 to 16.4) 
37 
(16.4 to 106.8) 
250 
(107.1 to 475) 
855 
(480 to 2375) 
Median (range): females 0 
8.2 
( 0.0006 to 28.6) 
87.9 
(28.6 to 190) 
360 
( 190.4 to 475) 
855 
(475.1 to 5937.5) 
Countryb (%) 
France 41.0 10.2 16.9 19.0 13.0 
Italy 45.1 23.8 24.8 5.9 0.4 
Spain 96.0 0.5 1.9 1.5 0.1 
UK 2.8 14.3 11.0 34.4 37.6 
Netherlands 10.5 8.0 23.1 44.3 14.2 
Greece 46.2 44.5 8.0 1.2 0.1 
Germany 24.1 6.0 35.4 26.3 8.2 
Sweden 52.4 16.6 13.3 12.6 5.1 
Denmark 16.1 19.3 20.8 10.0 33.8 
Norway NA NA NA NA NA 
Age a(years): Mean (SD) 53 (9) 50 (11) 50 (10) 51 (11) 53 (11) 
Sexb (%) 
males 35.3 17.4 15.2 18.2 14.0 
females 33.3 16.7 16.8 17.5 15.7 
Self reported diabetes mellitusb 
(%) 
No 33.6 17.1 16.5 17.9 15.0 
50
51
52
53
54
55
56
57
58
59
60
37 
 
Yes 47.5 15.4 13.7 12.9 10.5 
Unknown 31.2 13.9 12.6 17.5 24.9 
Educational levelb (%) 
None / Primary 53.1 16.5 13.4 8.8 8.1 
Technical/professional/secondary 27.7 17.6 18.1 20.3 16.4 
University degree/longer 24.1 17.0 17.7 22.6 18.7 
Not specified 11.2 12.9 11.2 30.2 34.5 
Smokingb (%) 
Never 33.3 16.6 16.4 18.5 15.2 
Former 29.8 15.7 16.5 20.1 17.8 
Current 40.8 19.2 15.8 12.9 11.3 
Unknown 29.9 16.8 15.1 20.0 18.2 
Ethanol Intake (g/day)b (%) 
low c 35.1 17.8 15.5 17.3 14.3 
moderate c 30.8 16.3 17.2 19.0 16.7 
high c 37.8 15.5 16.8 16.0 13.9 
Body Mass Index (kg/m2) b (%) 
     <=25 28.1 16.7 17.1 20.5 17.6 
>25 - <30 37.5 17.1 15.8 16.0 13.6 
>=30 46.2 17.5 14.5 11.9 10.0 
Physical Activity Index b (%) 
moderately inactived 38.6 17.1 15.1 15.6 13.7 
moderately actived 28.6 17.1 17.8 19.8 16.8 
unknown 12.9 9.3 19.8 38.3 19.7 
Energy Intake (kcal/day) : mean 
(SD) 2154.6 (691.5) 2053.1 (682.8) 2140.3 (698.3) 2084.2 (651.5) 2132.3 (672.2) 
50
51
52
53
54
55
56
57
58
59
60
38 
 
Total e (Number) 153,097 76,393 73,424 79,872 68,135 
a Categories of tea intake were defined as: non-consumers (C1); and the sex-specific quartiles among tea consumers (C2-C5) in the overall 
cohort. 
b Numbers in cells do not always add up to 100% horizontally due to rounding 
c Ethanol Intake: Low: Males:<10 g/day / Females:<5 g/day; Moderate: Males:10g/day to <40g/day / Females:5g/day to 20g/day; High: 
Males:>40 g/day; Females:>20 g/day.   
d Based on occupational physical activity and physical activity during cycling and sports 
e Norway is excluded due to lack of information about tea intake 
 
50
51
52
53
54
55
56
57
58
59
60
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Table 3. Hazard Ratios (HR) and 95% Confidence Intervals (CI) of hepatocellular carcinoma (HCC) incidence according to quintiles
a
 of 
coffee and categories
b
 of tea intake in the European Prospective Investigation into Cancer and nutrition cohort. 
HCC 
cases/N Model 1
c
 Model 2
d
 Model 3
e
 
HR 95% CI HR 95% CI HR 95% CI 
Coffee Intake 
(quintiles) 
Q1 47 / 98,148 1 
 
1 
 
1 
 Q2 49 / 100,953 0.96 (0.63 to 1.44) 0.91 (0.60 to 1.38) 0.85 (0.56 to 1.29) 
Q3 38 / 95,231 0.75 (0.46 to 1.19) 0.71 (0.44 to 1.14) 0.63 (0.39 to 1.02) 
Q4 36 / 96,413 0.67 (0.41 to 1.10) 0.61 (0.37 to 1.01) 0.49 (0.29 to 0.82) 
Q5 31 / 96,054 0.48 (0.28 to 0.82) 0.38 (0.22 to 0.66) 0.28 (0.16 to 0.50) 
P- trend 0.004 <0.001 <0.001 
Tea Intake 
(categories) 
C1  85 / 153,097  1 1 1 
C2 37 / 76,393  0.96 (0.62 to 1.49) 1.04 (0.67 to 1.61) 1.05 (0.68 to 1.63) 
C3 35 / 73,424 0.90 (0.58 to 1.41) 1.01 (0.65 to 1.58) 0.98 (0.63 to 1.53) 
C4 24/ 79,872 0.68 (0.40 to 1.16) 0.82 (0.48 to 1.41) 0.71 (0.41 to 1.23) 
C5 18 / 68,135  0.49 (0.27 to 0.89) 0.60 (0.32 to 1.10) 0.41 (0.22 to 0.78) 
P-trend 0.01 0.06 0.003 
Abbreviations: HR, Hazard ratio; CI, Confidence Interval; HCC, Hepatocellular carcinoma 
a Sex-specific quintiles (Q1-Q5) in the overall cohort 
bCategories of tea intake were defined as: non-consumers (C1); and the sex-specific quartiles among tea consumers (C2-C5) in the overall 
cohort.   
50
51
52
53
54
55
56
57
58
59
60
40 
 
cStratified for age at recruitment (in 1-year intervals) and for centre.  Adjusted for sex.  Norway was not included in analyses concerning tea 
intake as this information was not available.  
dStratified for age at recruitment (in 1-year intervals) and for centre.  Adjusted for sex, diabetes mellitus (self reported at enrolment), education, 
body mass index, smoking, physical activity, alcohol intake, categorically as in Table 2 and energy intake (ordered in quintiles). Norway was not 
included in analyses concerning tea intake as this information was not available.  
eAs model 2 but simultaneously including tea and coffee intake. Norway was not included in analyses concerning tea intake as this information 
was not available.  
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